Lao pharmaceutical industry pays close attention to the progress of monkeypox infection and makes initial plans

Date:2022-05-21 Views: 680 Times

Vientiane,Laos PDR, May 21, 2022 /LienTeh/

Yesterday,Members of several leading pharmaceutical companies in Laos discussed the spread of monkeypox and reached a preliminary plan.

Companies involved in the formulation of the plan include:RxLibra、SaiLin-Bio、BioSpring、DAXIONG Pharma...etc.

The above companies initially selected Tecovirimat as the treatment drug for monkeypox, and started to study the production formula.Once monkeypox spreads to Southeast Asia, a rapid response to public health and safety can be made immediately.Appropriate therapies will then be made available to the public through the ALBA team mechanism.

About Monkeypox spread

As of May 19, 2022, monkeypox cases have been reported in seven countries: Canada, Italy, Portugal, United Kingdom, Spain, Sweden, and the United States. On May 20, WHO reported that there were 37 confirmed cases of monkeypox globally and 71 suspected cases.

Monkeypox, a rare disease similar to smallpox, mainly occurs in west and central Africa, but related cases have also appeared in Europe and other parts of the world in recent years, CNN reported on the 19th. The cases are often linked to cross-border travel or cross-border animal trade, according to the Centers for Disease Control and Prevention (CDC).

According to the CDC, monkeypox has an incubation period of about 7 to 14 days after infection. The initial symptoms are often flu-like, such as fever, chills, exhaustion, headache and muscle weakness, before lymph nodes begin to swell, "a feature that distinguishes monkeypox infection from smallpox."

The United States has ordered 13 million additional doses of the monkeypox vaccine, worth $119 million, after a Massachusetts man contracted the rare but potentially serious virus, U.S. officials said Thursday.

About Monkeypox

Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. There are two distinct genetic clades of the monkeypox virus – the Central African (Congo Basin) clade and the West African clade. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible. The geographical division between the two clades has so far been in Cameroon - the only country where both virus clades have been found.

Monkeypox is usually a self-limited disease with the symptoms lasting from 2 to 4 weeks. Severe cases occur more commonly among children and are related to the extent of virus exposure, patient health status and nature of complications. Underlying immune deficiencies may lead to worse outcomes. Although vaccination against smallpox was protective in the past, today persons younger than 40 to 50 years of age (depending on the country) may be more susceptible to monkeypox due to cessation of smallpox vaccination campaigns globally after eradication of the disease.  Complications of monkeypox can include secondary infections, bronchopneumonia, sepsis, encephalitis, and infection of the cornea with ensuing loss of vision. The extent to which asymptomatic infection may occur is unknown.

The case fatality ratio of monkeypox has historically ranged from 0 to 11 % in the general population and has been higher among young children. In recent times, the case fatality ratio has been around 3-6%.

About Tecovirimat

Tecovirimat is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States.The drug works by blocking cellular transmission of the virus, thus preventing the disease. Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from monkeypox and rabbitpox and causes no serious side effects in humans.Two million doses of tecovirimat are stockpiled in the US Strategic National Stockpile should an orthopoxvirus-based bioterror attack occur.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.


ALBA TEAM is the system of persons acting in concert.It is a rapid response mechanism established to meet the challenges of public health crisis, major diseases and rare diseases.We hope that the cooperation among members can meet the outstanding medical needs.


RxLibra Pharmaceutical is a pharmaceutical industry service provider,It is THIRD PARTY PHARMA SERVICES focusing on Consulting services&Formulation manufacturing&Medicine exports.


DAXIONMG Pharmaceutical founded in 2020, it was established in Laos. Focusing on the research and development of generic drugs, focusing on the future. Daxiong Pharmaceutical stands on the shoulders of giants and is committed to achieving consistency with the original research in all aspects. Love Life Better Tommorow. Love life, beautiful tomorrow. Daxiong Pharmaceuticals.


Sailin biopharmaceutical (Laos) co., LTD., and the construction in 2019, is currently the largest and the most technologically advanced Laos anticancer and antiviral drugs production enterprise joint pharmaceutical group co., LTD., a subsidiary of the country's fastest growing large pharmaceutical companies.


BioSpring(laos) group Co.,LTD, established in 2022, Adhering to the concept of "Healing Beyond Boundaries", focusing on human and veterinary medicines, the goal is to become a leader in the pharmaceutical industry in Laos.